| pubmed-article:11438449 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C1514559 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C0025545 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C0597298 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:11438449 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
| pubmed-article:11438449 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11438449 | pubmed:dateCreated | 2001-7-4 | lld:pubmed |
| pubmed-article:11438449 | pubmed:abstractText | The third isoform (MT-3) of the metallothionein gene family is unique in that it has a limited tissue distribution, is not induced by metals, has a neuronal growth inhibitory activity, and sequesters zinc more effectively under zinc-depleted conditions. The goal of the present study was to determine whether MT-3 was absent in normal breast tissue, was overexpressed in breast cancers, and if MT-3 overexpression would be associated with disease outcome. A combination of immunohistochemistry and reverse-transcription polymerase chain reaction was used to demonstrate that the normal breast had no detectable expression of MT-3 mRNA or protein. Using immunohistochemistry, it was shown that MT-3 was overexpressed in 25 of 34 cases of breast cancer. In all cases of positive staining, MT-3 was diffusely localized to the cytoplasm. The tumors from these 34 cases were divided as to outcome based on known 5-year survival, with 20 patients being disease free at 5 years (good outcome) and the other 14 having recurring disease within 5 years (bad outcome). When analyzed for MT-3 staining, it was shown that there was a trend for increased MT-3 immunoreactivity in the group having bad outcomes. However, when the tumor subgrouping was further defined on the basis of carcinoma in situ (CIS), there was a marked significant difference in MT-3 staining between patients with good and bad outcomes. Limited to DCIS, MT-3 staining was significantly increased in patients with bad outcomes compared to those with good outcomes. Thus, these studies demonstrate that MT-3 is overexpressed in selected breast cancers and that overexpression is associated with tumors having a poor prognosis. | lld:pubmed |
| pubmed-article:11438449 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11438449 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11438449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11438449 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11438449 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:11438449 | pubmed:issn | 0002-9440 | lld:pubmed |
| pubmed-article:11438449 | pubmed:author | pubmed-author:BeallC LCL | lld:pubmed |
| pubmed-article:11438449 | pubmed:author | pubmed-author:SensD ADA | lld:pubmed |
| pubmed-article:11438449 | pubmed:author | pubmed-author:SensM AMA | lld:pubmed |
| pubmed-article:11438449 | pubmed:author | pubmed-author:GarrettS HSH | lld:pubmed |
| pubmed-article:11438449 | pubmed:author | pubmed-author:SomjiSS | lld:pubmed |
| pubmed-article:11438449 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11438449 | pubmed:volume | 159 | lld:pubmed |
| pubmed-article:11438449 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11438449 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11438449 | pubmed:pagination | 21-6 | lld:pubmed |
| pubmed-article:11438449 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:meshHeading | pubmed-meshheading:11438449... | lld:pubmed |
| pubmed-article:11438449 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11438449 | pubmed:articleTitle | Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. | lld:pubmed |
| pubmed-article:11438449 | pubmed:affiliation | Robert C. Byrd Health Sciences Center, Departments of Pathology and Urology, Program in Genetics and Developmental Biology, West Virginia University, Morgantown 26506-9203, USA. msens@hsc.wvu.edu | lld:pubmed |
| pubmed-article:11438449 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11438449 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11438449 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11438449 | lld:pubmed |
